Why Some Need Devices
When the electrical system is too broken to fix with drugs or ablation, you build a backup into the chest.
Ablation removes a bad actor. Drugs reshape the electrical environment. But some problems can't be removed or reshaped — they can only be guarded against.
Cardiac devices exist for three fundamentally different reasons, each rooted in a different failure of the heart's electrical system. Understanding those reasons requires understanding what's broken and why no other therapy can fix it.
Pacemakers: Replacing the Missing Spark
A pacemaker is prescribed when the heart's native impulse generation or conduction has failed beyond recovery. The mechanism is straightforward: either the sinus node no longer fires reliably (sinus node dysfunction), or the AV node / His-Purkinje system no longer conducts reliably (advanced heart block).
In both cases, the underlying problem is degenerative. Fibrosis has replaced the specialized conduction cells. The tissue that once generated or transmitted impulses has become electrically inert scar. No drug can revive dead conduction tissue, and there's nothing to ablate — the problem is absence, not presence.
The pacemaker provides what the biology no longer can: a guaranteed electrical impulse delivered at the right time, every time. A lead in the right ventricle ensures ventricular depolarization. A lead in the right atrium preserves AV synchrony. The device watches the native rhythm and only intervenes when it's needed — a concept called demand pacing.
The clock has failed. The atrial pacing lead takes over as the new clock, firing at a programmed base rate when the SA node doesn't.
The wiring between atria and ventricles is severed. The ventricular lead ensures the ventricles are depolarized in sync with atrial activity, restoring the coordinated contraction that the AV node once provided.
ICDs: The Last Line of Defense
An implantable cardioverter-defibrillator exists for one reason: to prevent sudden cardiac death. It's implanted when a patient carries a substrate that can, at any moment, generate ventricular fibrillation or sustained ventricular tachycardia fast enough to cause hemodynamic collapse.
The key concept is substrate. In ischemic cardiomyopathy, old infarct scars create a maze of surviving muscle fibers interwoven with dense fibrosis. These scar border zones are the substrate for reentrant VT — the same circuits described in Volume V. Any physiological trigger (a PVC, a surge of catecholamines, an electrolyte shift) can initiate a lethal spiral.
You can ablate the dominant VT circuit, but the scar contains many potential circuits. You can suppress triggers with beta-blockers or amiodarone, but you cannot guarantee suppression. The ICD doesn't prevent the arrhythmia from starting. It waits, senses the rhythm, recognizes when the ventricular rate crosses a dangerous threshold, and delivers therapy: antitachycardia pacing (ATP) to interrupt a monomorphic circuit, or a high-energy shock to reset ventricular fibrillation.
The logic is purely about lethality and unpredictability. If the substrate is dangerous, and if the arrhythmia can occur without warning, a device that is always present and always watching is the only therapy that provides a safety net.
CRT: Fixing the Squeeze
Cardiac resynchronization therapy addresses a problem that is simultaneously electrical and mechanical. In a heart with left bundle branch block, the left ventricle is activated late — the septum contracts first, and the lateral wall follows 80-150 ms behind. That delay means the two walls are fighting each other: one contracts while the other is still relaxing.
The mechanical consequence is a ventricle that squeezes inefficiently. Blood is shuffled back and forth inside the chamber rather than being ejected into the aorta. Over time, this dyssynchrony worsens heart failure. The ejection fraction drops, the ventricle dilates, and functional mitral regurgitation develops.
CRT corrects this by placing a pacing lead on the left ventricle (via the coronary sinus) and another on the right ventricle. By pacing both ventricles simultaneously (or with a precisely timed offset), the device forces both walls to contract at the same moment. The septum and lateral wall work together again. The heart squeezes in unison.
The electrical problem (LBBB) creates the mechanical problem (dyssynchrony). The device fixes the electrical timing, and the mechanical improvement follows. Patients who respond well can see a 10-15% improvement in ejection fraction, a reduction in mitral regurgitation, and reverse remodeling — the ventricle actually shrinks back toward a normal size.
The Common Thread
Every device implantation reflects the same underlying logic: the substrate cannot be removed or repaired by other means.
The conduction tissue has been destroyed by fibrosis. There's nothing to ablate and no drug that regenerates conduction cells. The device replaces the missing impulse.
The scar substrate harbors multiple potential lethal circuits. Ablation can reduce burden, drugs can suppress triggers, but neither can guarantee that VF will never occur. The device stands guard.
Conduction delay (LBBB) creates mechanical dyssynchrony. The delay is intrinsic to the damaged conduction system. The device imposes coordinated timing from the outside.
Secondary prevention is conceptually simple: a patient who has already survived VT/VF arrest carries the same substrate that produced the event. Without an ICD, the recurrence risk is high.
Primary prevention is the harder question. The patient has never had VT or VF, but carries a substrate that statistically predicts future events. The landmark trials (MADIT, SCD-HeFT) showed that patients with severe LV dysfunction (EF ≤ 35%) from ischemic or non-ischemic cardiomyopathy benefit from prophylactic ICD implantation — the device saves lives even before the first arrhythmia occurs.
The mechanistic reasoning: a severely dilated, scarred ventricle has all the ingredients for reentry. The trigger may not have arrived yet, but the substrate is already built. The ICD is insurance against a future that the substrate makes likely.
Key Takeaways
- Pacemakers replace failed impulse generation or conduction. Sinus node dysfunction and advanced AV block are degenerative, irreversible losses of specialized tissue. The device provides the spark that biology no longer can.
- ICDs guard against sudden death when the ventricular substrate is dangerous and unpredictable. They don't prevent arrhythmias — they detect and terminate them within seconds through ATP or shock.
- CRT corrects electrical dyssynchrony (typically LBBB) by pacing both ventricles simultaneously. The electrical fix restores mechanical coordination, improving ejection fraction and reversing remodeling.
- The common logic for all devices: the underlying substrate cannot be cured by ablation or drugs. The problem is structural, permanent, and requires hardware to manage.
- Primary prevention ICDs are implanted based on substrate risk (EF ≤ 35%), even before the first arrhythmic event. The scar is the loaded gun; the ICD prevents the bullet from killing the patient.